Oppenheimer Has Lowered Expectations for Soleno Therapeutics (NASDAQ:SLNO) Stock Price

Soleno Therapeutics (NASDAQ:SLNO) had its price objective reduced by investment analysts at Oppenheimer from $110.00 to $80.00 in a research note issued on Wednesday,Benzinga reports. The firm currently has an “outperform” rating on the stock. Oppenheimer’s price objective points to a potential upside of 138.02% from the company’s previous close.

Several other research firms have also issued reports on SLNO. Wolfe Research set a $60.00 price target on Soleno Therapeutics in a research report on Monday, January 12th. Robert W. Baird set a $107.00 price objective on Soleno Therapeutics in a research note on Tuesday, January 13th. TD Cowen cut their target price on shares of Soleno Therapeutics from $120.00 to $85.00 and set a “buy” rating on the stock in a report on Thursday, February 26th. HC Wainwright decreased their target price on shares of Soleno Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, March 4th. Finally, Zacks Research lowered shares of Soleno Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, February 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $104.54.

Soleno Therapeutics Stock Performance

NASDAQ SLNO opened at $33.61 on Wednesday. The company has a 50-day simple moving average of $39.78 and a two-hundred day simple moving average of $50.21. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. Soleno Therapeutics has a 12-month low of $32.15 and a 12-month high of $90.32. The firm has a market cap of $1.73 billion, a price-to-earnings ratio of 146.14 and a beta of -3.16.

Soleno Therapeutics (NASDAQ:SLNO) last released its quarterly earnings data on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million during the quarter, compared to analysts’ expectations of $88.55 million. On average, equities analysts forecast that Soleno Therapeutics will post -3.72 EPS for the current year.

Institutional Investors Weigh In On Soleno Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Soleno Therapeutics by 1.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company’s stock worth $1,242,000 after buying an additional 189 shares during the last quarter. Raymond James Financial Inc. purchased a new position in Soleno Therapeutics during the second quarter valued at $25,000. Avanza Fonder AB raised its stake in Soleno Therapeutics by 11.2% during the fourth quarter. Avanza Fonder AB now owns 3,195 shares of the company’s stock valued at $148,000 after buying an additional 323 shares during the last quarter. Principal Financial Group Inc. boosted its holdings in Soleno Therapeutics by 11.9% in the third quarter. Principal Financial Group Inc. now owns 3,197 shares of the company’s stock worth $216,000 after acquiring an additional 340 shares in the last quarter. Finally, New York State Common Retirement Fund boosted its holdings in Soleno Therapeutics by 2.4% in the third quarter. New York State Common Retirement Fund now owns 15,600 shares of the company’s stock worth $1,055,000 after acquiring an additional 360 shares in the last quarter. 97.42% of the stock is owned by hedge funds and other institutional investors.

Soleno Therapeutics News Roundup

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Oppenheimer kept an “outperform” rating while lowering its price target to $80, signaling continued analyst conviction in Soleno’s longer-term upside despite the cut. Oppenheimer Price Target Note
• Neutral Sentiment: Multiple firms are circulating investor alerts and reminders about a May 5, 2026 deadline to seek lead-plaintiff status, increasing visibility of the litigation but not by itself changing the legal facts; this activity typically raises short-term trading volume and news flow. Example notices include Rosen, Bernstein Liebhard, Kessler Topaz and others. Rosen Law Firm Notice
• Negative Sentiment: A securities class action has been filed alleging that Soleno made material misstatements/omissions about its Phase 3 program and that November 2025 disclosures about DCCR (VYKAT™ XR) launch disruptions harmed investors; several firms (Hagens Berman, Bronstein Gewirtz, Bernstein Liebhard, Kessler Topaz, Levi & Korsinsky, etc.) are pursuing claims. These filings elevate legal and financial risk and could pressure the stock if damages or penalties are pursued. Hagens Berman Lawsuit Notice
• Negative Sentiment: Some alerts specifically reference allegations about clinical-trial integrity and even “sham clinical trials,” which, if proven, would be materially adverse for regulatory, commercial and reputational prospects for VYKAT™ XR. Expect continued press releases from law firms and elevated volatility. SueWallSt Alert

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company’s scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company’s lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.